LaNova Medicines (Zhejiang) Co., Ltd.

DUBLIN, June 16, 2023 /PRNewswire/ -- The "Global Cancer Antibody Drug Conjugates Market Size, Drug Sales, Drug Dosage, Price, & Clinical Trials Outlook 2029" report has been added to ResearchAndMarkets.com's offering. Global Cancer Antibody Drug Conjugates Market Size, Drug Sales, Drug Dosage, Price, & Clinical Trials Outlook 2029 Report Highlights: Global Antibody Drug Conjugates Market Opportunity: > 40 Billion By 2029 Global & Regional Antibody Drug Conjugate Market Insight Approved Drugs Sales Insight Global & Regional, Yearly & Quarterly, 2019 -2023 Approved Antibody Drug Conjugates - Availability, Dosage & Price Insight Insight On Antibody Drug Conjugates In Clinical Trials: > 550 Drugs Insight On Commercially Approved Antibody Drug Conjugates: > 15 Drugs Cancer Antibody Drug Conjugates Clinical Pipeline By Company, Indication & Phase Global Cancer Antibody Drug Conjugate Market Trends by Indication The realm of cancer treatment is experiencing a surge of innovation that may greatly change how we currently diagnose as well as treat cancer. Clinical researchers and pharmaceutical companies continue to seek innovative solutions that offer enhanced efficacy and reduced side effects. Among the ongoing significant advancements, antibody drug conjugates (ADCs) have emerged as a groundbreaker in cancer therapeutics. This rapidly expanding market is transforming the treatment landscape, offering a new therapeutic option for patients globally. Antibody drug conjugates harness the synergistic potential of monoclonal antibodies and potent cytotoxic drugs, delivering a strong strike against cancer cells. By exploiting the specificity of monoclonal antibodies, antibody drug conjugates can selectively bind to cancer antigens, increasing drug delivery directly to tumor sites. This targeted approach enables higher drug concentrations at the desired location while minimizing harm to healthy, normal tissues. The antibody drug conjugate market is experiencing remarkable growth, driven by several key factors including the increasing cancer incidence rates, rowing demand for effective and personalized treatment options and advancements in antibody engineering and drug delivery technologies are propelling the market forward. Moreover, regulatory approvals have opened the way for the commercial success of antibody drug conjugates which has further encouraged investments in the field. For instance, Adcetris and Kadcyla have been in the market for a long time and their commercial sales hold a significant share of the current antibody drug conjugate market. The growth of these antibody drug conjugates represents the significant need for this therapeutic modality. Enhertu, another antibody drug conjugate which is relatively new to the market compared to Kadcyla and Adcetris, has shown immense success commercially. With its recent approval for breast cancer indication, the sales for Enhertu have escalated rapidly. Antibody drug conjugates have welcomed a new age of targeted cancer therapy and this novel class of cancer treatment can be evaluated to have an exponential increase in terms of both commercial success as well as expansion of the global portfolio. However, the development of antibody drug conjugates has been associated with significant challenges with difficulties in manufacturing, bioconjugation and their overall development. Nevertheless, collaboration between pharmaceutical companies and academic institutions has been an important factor that has helped in overcoming these limitations, resulting in such success of antibody drug conjugates. For instance, Lantern Pharma collaborating with Germany's Bielefeld University will leverage its proprietary Artificial Intelligence platform RADR for the rapid development of novel cryptophycin antibody drug conjugates, representing an exciting new class of strong and highly directed drug candidates. It is expected that outcomes from this collaborative arrangement will pave the way for next generation antibody drug conjugated designed using AI with high efficacy, swift development with sibilant cost reduction. The future of antibody drug conjugates is expected to be closely tangled with technological innovations. Novel conjugation strategies such as site specific conjugation are also being explored to enhance stability of antibody drug conjugates, resulting in improved therapeutic outcomes. Additionally, advancements in bioconjugation techniques, payload release mechanism and drug delivery systems offer opportunities to optimize the pharmacokinetics and bio distribution of antibody drug conjugates potentially increasing their effectiveness. Antibody drug conjugates have targeted a new level of efficacy, surpassing the capabilities of traditional monoclonal antibodies and opening opportunities for market expansion. While monoclonal antibodies are highly specific in their binding to cancer cell antigens, their therapeutic impact often relies on the activation of immune responses or blocking signaling pathways. In contrast, antibody drug conjugates offer a multifaceted approach by directly delivering a potent cytotoxic payload to cancer cells, exerting a direct cell killing effect. Overall, the antibody drug conjugates market represents a groundbreaking approach to cancer treatment. As market continues to expand, patients and healthcare professionals are witnessing significant advancements. With ongoing research, technological innovations and strategic collaborations, the future of antibody drug conjugates is set to transform the global cancer therapy market. This report provides a comprehensive analysis about the currently approved antibody drug conjugates in terms of their patent, price, dosage as well as their sales and treatment cost. Furthermore, the report also provides information about the regional impact of approved antibody drug conjugates while also providing information about the possible future opportunities in the global antibody drug conjugates market. Key Topics Covered: 1. Introduction to Antibody Drug Conjugates 1.1 Overview 1.2 Historical Development of ADCs 1.3 Evolution of Antibody Drug Conjugates 2. Need of Antibody Drug Conjugates 3. Global Antibody Drug Conjugate Market Insight 3.1 Current Market Scenario (2019 -2023) 3.2 Future Market Opportunity Assessment 2029 4. Antibody Drug Conjugate Market Regional Analysis 4.1 US 4.2 China 4.3 South Korea 4.4 India 4.5 Australia 4.6 Europe 4.7 Canada 4.8 Japan 4.9 Taiwan 5. Global Cancer Antibody Drug Conjugate Market Trends by Indication 5.1 Breast Cancer 5.2 Lung Cancer 5.3 Lymphoma 5.4 Leukemia 5.5 Cervical Cancer 5.6 Urothelial Cancer 5.7 Gastric Cancer 5.8 Other Cancers 6. Approved Antibody Drug Conjugates - Availability, Dosage & Price Insight 2023 6.1 Mylotarg 6.2 Adcetris 6.3 Kadcyla 6.4 Besponsa 6.5 Lumoxiti 6.6 Polivy 6.7 Padcev 6.8 Enhertu 6.9 Trodelvy 6.10 Blenrep 6.11 Zynlonta 6.12 Tivdak 6.13 Elahere 6.14 Aidixi 6.15 Ujvira 6.16 Akalux 7. Approved Antibody Drug Conjugate Sales Insights (Global & Regional, Yearly & Quarterly, 2019 -2023) 7.1 Adcetris 7.2 Padcev 7.3 Tivdak 7.4 Polivy 7.5 Kadcyla 7.6 Besponsa 7.7 Enhertu 7.8 Trodelvy 7.9 Zynlonta 7.10 Elahere 7.11 Blenrep 8. Global Antibody Drug Conjugates Clinical Trials Insight 2023 8.1 By Phase 8.2 By Indication 8.3 By Company 8.4 By Patient Segment 8.5 By Country 9. Global Cancer Antibody Drug Conjugates Clinical Pipeline By Company, Indication & Phase 9.1 Research 9.2 Preclinical 9.3 Phase-I 9.4 Phase-I/II 9.5 Phase-II 9.6 Phase-II/III 9.7 Phase-III 9.8 Preregistration 10. Marketed Cancer Antibody Drug Conjugates Clinical Insight 11. Global Cancer an Antibody Drug Conjugates Market Dynamics 11.1 Favorable Parameters 11.2 Challenges for Antibody Drug conjugates Market 12. Competitive Landscape 12.1 AbbVie 12.2 ADC Therapeutics 12.3 AstraZeneca 12.4 Bayer 12.5 BiOneCure Therapeutics 12.6 Biosion 12.7 Bio-Thera Solutions 12.8 Boehringer Ingelheim 12.9 Daiichi Sankyo Company 12.10 Duality Biologics 12.11 Exelixis 12.12 Genmab 12.13 Hangzhou DAC Biotech 12.14 Heidelberg Pharma AG 12.15 Iksuda Therapeutics 12.16 ImmunoGen 12.17 LaNova Medicines Limited 12.18 LegoChem Biosciences 12.19 Lepu Biopharma 12.20 Mersana Therapeutics 12.21 Molecular Templates 12.22 Multitude Therapeutics 12.23 NanoValent Pharmaceuticals 12.24 NewBio Therapeutics 12.25 Orum Therapeutics 12.26 ProfoundBio 12.27 Radiopharm Theranostics 12.28 Seagen 12.29 Sorrento Therapeutics 12.30 Sutro Biopharma For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

AstraZeneca is making ADC moves in Asia once again, this week that it has entered a license agreement with Shanghai-based LaNova Medicines, in a deal that could be valued up to $600 million. Under the terms of the collaboration, LaNova will receive upfront and near-term payments of up to $55 million and additional development and commercial milestone payments of up to $545 million. In exchange, AstraZeneca will receiveglobal license to research, develop, and commercialize LM-305.LM-305, LaNova’s GPRC5D-targeting antibody-drug conjugate, is the second to emerge from the company’s proprietary ADC platform. The ADC is made up of an anti-GPRC5D monoclonal antibody, a protease-degradable linker, and a cytotoxic payload monomethyl auristatin E (MMAE). The drug has obtained IND approvals in both the U.S. and China. LaNova Medicines is a young biotech, first established in 2019. The company has over 10 drug candidates, with its three lead candidates currently in phase 1/2 studies. This is the second ADC deal inked by AstraZeneca this year. Back in , the drugmaker signed a deal worth up to $1.1 billion with KYM Biosciences, a joint venture established by Chinese biotechs Keymed Biosciences and Lepu Biopharma. The licensing agreement is forKYM'spotential first-in-class ADC targeting Claudin 18.2.

A candidate from LaNova Medicines slots into a growing portfolio of antibody-drug conjugates in development at AstraZeneca. AstraZeneca’s search for antibody-drug conjugates has again led to Asia. This time around, the Anglo-Swedish drugmaker is committing up to $55 million in upfront and near-term payments to secure global rights and join an intensifying race to offer options to patients who relapse after BCMA therapy. The agreement sees AstraZeneca pay LaNova Medicines an upfront fee and sweeten the deal with up to $545 million in milestones to get its hands on the preclinical, GPRC5D-directed prospect LM-305. Inking the deal establishes AstraZeneca as a rival to Bristol Myers Squibb, Johnson & Johnson, Roche and other companies that see GPRC5D as a way to unlock the potentially lucrative post-BCMA patient population.  Those four pharma companies are part of a long list of drug developers that have thrown almost the full spectrum of modalities at BCMA in recent years, culminating in the approvals of BMS’ Abecma and J&J’s Carvykti. With their high response rates, those CAR-T cell therapies and other BCMA drugs look set to transform the treatment of multiple myeloma in the coming years. But with data suggesting most patients will eventually relapse, there is an unmet need for a later-line, post-BCMA treatment. GPRC5D could be just that. Scientists have found the receptor in several myeloma cell lines and in bone marrow plasma cells from patients with the cancer. Otherwise, expression is limited to low levels in the skin and testes, suggesting drug developers can create therapies with minimal on-target, off-tumor effects. AstraZeneca’s selection of ADC as the modality for going after GPRC5D sets it apart from the front-runners in the space, although the company has also ceded a head start to some rivals. BMS' anti-GPRC5D CAR-T therapy saw an 86% response rate in recipients during a small clinical trial, including responses in people previously treated with BCMA treatments. J&J and Roche have GPRC5D bispecifics in the clinic. LaNova secured a green light to test LM-305 in humans in China late last year, putting it years behind the leading programs. But the complete responses and safety profile seen in tests in mice have persuaded AstraZeneca that the candidate has a shot at coming from behind and claiming a slice of the market.  The candidate slots into a growing portfolio of ADCs in development at AstraZeneca, which secured rights to HER2 ADC Enhertu and the TROP2-directed DS-1062 through partnerships with Daiichi Sankyo in 2019 and 2020 and recently paid KYM Biosciences for the global rights to a Claudin18.2 prospect.